Katarzyna Swiderska

Gliwice Branch
Gliwice, SL 44102, Poland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland.

Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: March 25, 2026

Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.

Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.

Journal: Breast cancer research : BCR
Published: September 17, 2025

Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors.

Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors.

Journal: BMC cancer
Published: June 18, 2025

Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer.

Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer.

Journal: NPJ breast cancer
Published: February 11, 2025

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting.

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting.

Journal: Frontiers in oncology
Published: June 25, 2024

Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis.

Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis.

Journal: Frontiers in oncology
Published: March 28, 2024

Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study.

Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study.

Journal: Acta oncologica (Stockholm, Sweden)
Published: March 26, 2024

Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience.

Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience.

Journal: Oncology letters
Published: December 20, 2023

Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients.

Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients.

Journal: Cancers
Published: November 11, 2023

Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer.

Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer.

Journal: Cancers
Published: December 16, 2022
Showing 1-10 of 10

Last Updated: 09/26/2026